Everything below concerns prothymosin alpha. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-05. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Long-term storage is generally at minus twenty degrees Celsius or colder, preferably desiccated and protected from light. Lyophilized material is more stable than reconstituted solution, which degrades faster at room temperature. Stability depends on pH, ionic strength, and the presence of oxidising agents. Published stability data for the peptide are limited, so storage claims in catalogues should be treated as general guidance rather than measured guarantees. Freeze-thaw cycles are kept to a minimum.
Identity and purity are normally confirmed by reversed-phase high-performance liquid chromatography and mass spectrometry. The expected mass for the acetylated 28-residue peptide is close to 3108 daltons, and a mass shift indicates a modification or truncation. Peptide mapping after enzymatic digestion can resolve sequence-level questions. Counter-ion content, water content, and residual solvents are separate quality attributes that a certificate of analysis may or may not report. Aggregation is monitored by size-exclusion chromatography when relevant.
Thymosin alpha-1 is supplied as a lyophilized powder in most research settings. The solid dissolves readily in water and in common aqueous buffers, and it is typically reconstituted shortly before use. Solutions are clear and colourless at ordinary working concentrations. Because the peptide is hygroscopic, weighing and reconstitution are usually performed with minimal exposure to ambient air. Aliquots are prepared to avoid repeated freeze-thaw cycles, and working solutions are kept cold.
| Property | Value | Notes |
|---|---|---|
| Amino acid length | 28 residues | Single chain with an acetylated N-terminus |
| Molecular mass | Approximately 3,108 Da | Small shifts occur with counter-ion and water content |
| Isoelectric point | Around 3.5 | Low value follows from the many acidic residues |
| Parent molecule | N-terminal region of prothymosin alpha | Free circulating form in humans is not firmly established |
| Common synonyms | Thymalfasin; T alpha 1 | Older literature also uses the full spelled-out form |
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
Stability depends on temperature, pH, and the number of freeze-thaw events the sample has experienced. Freeze-dried material is commonly held at -20 °C or colder, while reconstituted liquid is kept cold and used within a short window. Extreme pH and prolonged light exposure can promote deamidation, oxidation, or aggregation, particularly at asparagine and methionine positions. Adsorption to container walls can lower the measured concentration of a dilute solution even when the peptide molecules themselves remain intact.
Recommended storage for the dry powder is a freezer near minus twenty degrees Celsius, kept desiccated and away from light. Once dissolved, the peptide is less stable and is usually held at two to eight degrees Celsius for short intervals or frozen for longer storage. Stability studies focus on the acetylated terminus and the disulfide linkage because those features define the intact molecule. Common degradation routes include cysteine oxidation, deamidation of asparagine or glutamine side chains, and slow formation of higher-molecular-weight species.
Identity and purity are usually checked by reverse-phase high-performance liquid chromatography, which separates the intact chain from truncated products, together with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion and amino acid analysis add sequence-level evidence. Release testing also covers water content, residual solvents, and counter-ions, all of which influence measured mass and stability. Related-peptide limits are commonly expressed as a percentage of total peak area, with individual unspecified impurities held below a lower threshold.
Thymosin alpha 1 is a synthetic 28-amino-acid peptide first isolated in 1966 from thymosin fraction 5, a bovine thymus extract. Its chain begins with an acetylated serine residue and ends with asparagine. The native peptide carries a molecular mass near 3,108 daltons. Researchers classify it as an immunomodulatory agent rather than a hormone with a single endocrine target. Early work framed it as a thymus-derived factor that supports T-cell maturation. The synthetic form used in research and clinical products matches the natural sequence.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
在信号层面，Tα1可能通过Toll样受体等模式识别受体发挥作用。部分实验显示，它能激活髓样分化因子88依赖的通路，进而促进核因子κB进入细胞核。这导致白细胞介素2、干扰素γ和白细胞介素12等细胞因子的转录增加。这些细胞因子偏向辅助性T细胞1型应答，有助于细胞免疫。然而，具体受体和结合位点尚未完全确定，不同实验模型的结果存在差异。
临床研究将Tα1用于慢性病毒感染、肿瘤辅助治疗和疫苗佐剂等场景。部分试验报告了免疫学指标改善，但临床终点获益在不同研究中并不一致。系统综述指出，研究间在人群、剂量和联合方案上差异较大，难以汇总结论。因此，Tα1的确切临床地位仍属开放问题，需要更多高质量随机对照试验来澄清。其机制研究也需从体外实验向体内模型推进。
胸腺素α1对免疫系统的影响涉及多种细胞类型。研究表明，它可促进未成熟T细胞向成熟T细胞分化，并增强T细胞对抗原刺激的增殖反应。树突状细胞在Tα1存在下表达更高水平的共刺激分子，从而更有效地呈递抗原。此外，自然杀伤细胞的活性也观察到上升。这些效应并非直接杀伤病原体，而是调节宿主免疫应答的强度与方向。
TCM is said to be based on such texts as Huangdi Neijing (The Inner Canon of the Yellow Emperor), and Compendium of Materia Medica, a sixteenth-century encyclopedic work, and includes various forms of herbal medicine, acupuncture, cupping therapy, gua sha, massage (tui na), bonesetter (die-da), exercise (qigong), and dietary therapy. TCM is widely used in the Sinosphere. One of the basic tenets is that the body's qi is circulating through channels called meridians having branches connected to bodily organs and functions. There is no evidence that meridians or vital energy exist. Concepts of the body and of disease used in TCM reflect its ancient origins and its emphasis on dynamic processes over material structure, similar to the humoral theory of ancient Greece and ancient Rome. The demand for traditional medicines in China is a major generator of illegal wildlife smuggling, linked to the killing and smuggling of endangered animals. The Chinese authorities have engaged in attempts to crack down on illegal TCM-related wildlife smuggling.
== Therapies == A decade after the discovery of the RNAi mechanism in 1998, the pharmaceutical sector heavily invested in the research and development of siRNA therapy. There are several advantages that this therapy has over small molecules and antibodies. It can be administered quarterly or every six months. Another advantage is that, unlike small molecules and monoclonal antibodies that need to recognize a specific protein conformation, siRNA functions by Watson-Crick basepairing with mRNA. Therefore, any target molecule that needs to be treated with high affinity and specificity can be selected if the right nucleotide sequence is available. One of the biggest challenges researchers needed to overcome was the identification and establishment of a delivery system through which the therapies would enter the body. Another was that the immune system often mistakes RNAi therapies for remnants of infectious agents, which can trigger an immune response. Animal models did not accurately represent the degree of immune response seen in humans, and despite the promise of the treatment, investors divested from RNAi. However, there were a few companies that continued with the development of RNAi therapy for humans. Alnylam Pharmaceuticals, Sirna Therapeutics and Dicerna Pharmaceuticals are few of the companies still working on bringing RNAi therapies to market. It was learned that almost all siRNA therapies administered in the bloodstream accumulated in the liver. That is why most of the early drug targets were diseases that affected the liver.
from ectoderm (e.g., the epidermis); from endoderm (e.g., the lining of the gastrointestinal tract); from mesoderm (e.g., the inner linings of body cavities). However, pathologists do not consider endothelium and mesothelium (both derived from mesoderm) to be true epithelium. This is because such tissues present very different pathology. For that reason, pathologists label cancers in endothelium and mesothelium sarcomas, whereas true epithelial cancers are called carcinomas. Additionally, the filaments that support these mesoderm-derived tissues are very distinct. Outside of the field of pathology, it is generally accepted that the epithelium arises from all three germ layers.
At the time, the multiple neutron absorption was thought to be an extremely rare process, but the identification of 244Pu indicated that still more neutrons could have been captured by the uranium, producing new elements heavier than californium.
Sources: en.wikipedia.org
== Assembly == Direct interaction of two nascent proteins emerging from nearby ribosomes appears to be a general mechanism for oligomer formation. Hundreds of protein oligomers were identified that assemble in human cells by such an interaction. The most prevalent form of interaction was between the N-terminal regions of the interacting proteins. Dimer formation appears to be able to occur independently of dedicated assembly machines.
can be interpreted as the cumulative number of diagnoses (including individuals who have recovered) or the present number of infection cases; the logarithmic growth rate is the same for either definition. In order to estimate
Two adults and five children at the Kindercare kindergarten in Christchurch suffer chemical burns after being accidentally exposed to a hazardous substance being poured on a waterslide. The Controller and Auditor-General of New Zealand launches an investigation into the Chatham Islands Council's expenditure and procurement policies. Craig Stobo temporarily steps down as chairperson of the Financial Market Authority pending an investigation by the Ministry of Business, Innovation and Employment (MBIE). 6 December — A measles case is reported in Queenstown, bringing the total number of cases reported nationally to 30. 22 cases are no longer infectious. 8 December: A wildfire engulfs over 320 hectares of Tongariro National Park, leading to the closure of sections of State Highway 47. Significant firefighting resources including 60 firefighters, 16 vehicles and nine helicopters are deployed to contain the blaze. The National Iwi Chairs Forum delivers a 24,000-strong petition urging the Education Minister Erica Stanford to reverse an amendment abolishing the requirement for school boards to uphold the Treaty of Waitangi. 9 December: The Supreme Court of New Zealand rules that two parents who care for their severely disabled adult children should be recognised as homeworkers who are entitled to the minimum wage. The New Zealand Government announces two proposed bills to replace the Resource Management Act 1991.
=== University technology transfer === Despite the ethical, academic, commercial, and therapeutic controversies surrounding the identity and efficacy of "tethelin" itself (see below), Robertson's (1917) assignment of his tethelin patent to the University of California is universally treated as a landmark precedent event in the development of university technology transfer. In the ensuing years, the emergence of the concept of "intellectual property", driven by the theories and influence of Henri Bergson (the (August 1922) inaugural chairman of the League of Nations Committee on Intellectual Cooperation), made the already complex "paper vs. patent" issue even more fiercely contested, due to the significantly increased number of patents and the number of universities involved, and the extent to which a university's ever-increasing move towards commercialization not only reduced that institution's focus on the production of knowledge, but also privatised the knowledge that its researchers produced (PS.1):
=== June === 1 June – Aberdeen and Edinburgh become the latest Scottish cities to introduce low emission zones. 2 June – A memorial service is held at Southend Parish Church to mark the 30th anniversary of the 1994 RAF Chinook disaster in which 29 passengers and crew were killed. 3 June – The first 2024 general election leaders debate takes place in Scotland, with the leaders of Scotland's four main political parties taking part in a debate on STV. 5 June – Alba Party leader Alex Salmond confirms he will not stand in the general election, but instead plans to stand in the 2026 Scottish Parliament election in Banff and Buchan. 7 June – At the High Court in Edinburgh, council worker Michael Paterson admits to embezzling more than £1m from Aberdeen City Council while employed as a council tax and recovery team leader between 2006 and 2023. 9 June – The Sunday Mail reports allegations that Scottish Conservative leader Douglas Ross used Westminster expenses to travel in his role as a football linesman. 10 June – Douglas Ross announces his resignation as leader of the Scottish Conservatives, triggering a leadership election. Ross says he will also resign from Holyrood if he is re-elected to Westminster. 11 June – BBC Scotland airs an election debate featuring the leaders of Scotland's five main political parties: John Swinney (SNP), Douglas Ross (Scottish Conservatives), Anas Sarwar (Scottish Labour), Alex Cole-Hamilton (Scottish Liberal Democrats) and Lorna Slater (Scottish Greens).
Sources: en.wikipedia.org
=== Ebola === After initial studies by the Centers for Disease Control and Prevention (CDC, Atlanta, Georgia, US) in cell culture models, on 6 October 2014, Chimerix received an FDA authorization for emergency investigational new drug applications of brincidofovir for the treatment of Ebola virus disease. Brincidofovir was administered to the first patient diagnosed in the Ebola virus disease outbreak in the US in 2014. The patient was given the drug starting six days after hospital admission when he was already critically ill; he died four days later. Brincidofovir was also given to Ebola patient Ashoka Mukpo at the Nebraska Medical Center, who had developed the disease and then was pronounced Ebola-free and released from the center on 22 October 2014. In October 2014, Chimerix reported it had been given approval by the FDA to start Phase 2 trials in patients infected with ebolaviruses for brincidofovir's safety, tolerability, and efficacy. Organised by a team of scientists at the University of Oxford, including Peter Horby, Jake Dunning, Laura Merson and Trudie Lang, a trial commenced during January 2015 in Liberia, but was subsequently discontinued. Because of a lack of suitable subjects in Liberia, Oxford University and Médecins Sans Frontières planned to extend the trial to Sierra Leone, where there were still Ebola cases; but on 30 January 2015, the manufacturer decided to withdraw support for the trial and end discussion of future trials.
Pancrustacea is the clade that comprises all crustaceans and all hexapods (insects and relatives). This grouping is contrary to the Atelocerata hypothesis, in which Hexapoda and Myriapoda are sister taxa, and Crustacea are only more distantly related. As of 2010, the Pancrustacea taxon was considered well accepted, with most studies recovering Hexapoda within Crustacea. The clade has also been called Tetraconata, referring to having a four-part cone in the ommatidium. The term "Tetraconata" is preferred by some scientists in order to avoid confusion with the use of "pan-" to indicate a clade that includes a crown group and all of its stem group representatives.
The positions of president laboratory director and deputy laboratory director are filled by joint action of the chair and vice chair of the executive committee, with the University of California nominating the president and laboratory director and Bechtel nominating the deputy laboratory director. The current LLNS chairman is Norman J. Pattiz, founder and chairman of Westwood One, America's largest radio network, who also currently serves on the board of regents of the University of California. The vice chairman is J. Scott Ogilvie, president of Bechtel Systems & Infrastructure, Inc., who also serves on the board of directors of Bechtel Group, Inc. (BGI) and on the BGI Audit Committee.
Weather observation quality control systems verify probability, history, and trends. One of the main and simplest forms of quality control is the check of probability. This check throws out impossible observations, such as the dew point being higher than the temperature or data outside acceptable ranges, such as temperatures over 200 degrees Fahrenheit. Another basic quality control check is to have the data compared to preset geographic extremes, perhaps combined with diurnal variations. However this only flags the data as uncertain because the station could be reporting correctly but there is no way to know. A better way is to correlate with previous observations as well as the other simple checks. This method uses one hour persistence to check the quality of the current observation. This method makes continuity of observations better since the system is able to make better judgments on whether the current observations are bad or not.
Sources: en.wikipedia.org
It is usually described as an immunomodulatory peptide rather than a classic circulating hormone. No endocrine gland is known to release it as a primary secretory product, and its measured presence in blood is not firmly established.
Prothymosin alpha is a much larger acidic protein, roughly 111 to 113 residues long, and the thymosin alpha-1 sequence matches its N-terminal region. The small peptide is therefore best understood as a fragment of that parent protein rather than a separate gene product.
Trials and clinical reports have examined chronic hepatitis B and C, use as a vaccine adjuvant, and supportive treatment in some immunodeficiency and oncology settings. Results vary by indication, and regulatory approval differs between countries.
Lyophilized powder is normally kept at minus twenty degrees Celsius or below, in a sealed container, desiccated and away from light. Reconstituted solutions are less stable and are usually refrigerated and used quickly. Repeated temperature cycling should be avoided.